Invention Grant
- Patent Title: Quinoline derivatives as kinase inhibitors
- Patent Title (中): 喹啉衍生物作为激酶抑制剂
-
Application No.: US13508956Application Date: 2010-11-11
-
Publication No.: US08653105B2Publication Date: 2014-02-18
- Inventor: Daniel Rees Allen , Roland Bürli , Alan Findlay Haughan , Mizio Matteucci , Andrew Pate Owens , Gilles Raphy , Andrew Sharpe
- Applicant: Daniel Rees Allen , Roland Bürli , Alan Findlay Haughan , Mizio Matteucci , Andrew Pate Owens , Gilles Raphy , Andrew Sharpe
- Applicant Address: BE Brussels
- Assignee: UCB Pharma S.A.
- Current Assignee: UCB Pharma S.A.
- Current Assignee Address: BE Brussels
- Agency: McDonnell Boehnen Hulbert & Berghoff LLP
- Priority: GB0919829.2 20091112; GB1012102.8 20100719
- International Application: PCT/EP2010/067304 WO 20101111
- International Announcement: WO2011/058108 WO 20110519
- Main IPC: A61K31/4709
- IPC: A61K31/4709 ; C07D401/14 ; C07D215/50

Abstract:
A series of quinoline derivatives, substituted by an optionally substituted bicyclic heteroaryl moiety consisting of two fused six-membered aromatic rings attached via an alkylene chain optionally linked to a heteroatom, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.
Public/Granted literature
- US20130012517A1 Quinoline and Quinoxaline Derivatives as Kinase Inhibitors Public/Granted day:2013-01-10
Information query
IPC分类: